Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Title

Type your Poster Title, then hit apply

Showing 1,267 results.

Thumbnail for Understanding the Symptom Burden and Health-Related Quality of Life Among Black Patients With Multiple Myeloma: A Retrospective Analysis of Patient-Reported Data

MM - 220

Understanding the Symptom Burden and Health-Related Quality of Life Among Black Patients With Multiple Myeloma: A Retrospective Analysis of Patient-Reported Data

Osborn Owusu Ansah

Poster Presenter: Osborn Owusu Ansah

Thumbnail for Unmasked by Coagulopathy: NPM1-Mutated AML with APL-Like Features

AML - 567

Unmasked by Coagulopathy: NPM1-Mutated AML with APL-Like Features

Mai Salem

Poster Presenter: Mai Salem

Thumbnail for Update From the Phase 2 RESTORE Trial of Elritercept in Patients With Myelofibrosis Receiving Ruxolitinib

Previous 1...133 134 135 136 137 138 139...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

MPN - 832

Update From the Phase 2 RESTORE Trial of Elritercept in Patients With Myelofibrosis Receiving Ruxolitinib

Ciro Rinaldi

Poster Presenter: Ciro Rinaldi

$Thumbnail for Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis From IMbark Versus Real-World Data and Assessment of Real-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow-Up$

MPN - 269

Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis From IMbark Versus Real-World Data and Assessment of Real-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow-Up

Andrew T Kuykendall

Poster Presenter: Andrew T Kuykendall

Thumbnail for Updated Clinical Data From the Phase 1 Study of Dibotatug (DR-01), a Nonfucosylated Anti-CD94 Antibody, in Patients With Large Granular Lymphocytic Leukemia

TCL - 418

Updated Clinical Data From the Phase 1 Study of Dibotatug (DR-01), a Nonfucosylated Anti-CD94 Antibody, in Patients With Large Granular Lymphocytic Leukemia

Tapan Kadia

Poster Presenter: Tapan Kadia

$Thumbnail for Updated Clinical Data from the Phase 1/2 Study of Dibotatug (DR-01), a Non-Fucosylated Anti-CD94 Antibody, in Patients with Relapsed/Refractory Cytotoxic T/NK cell Lymphomas$

TCL - 416

Updated Clinical Data from the Phase 1/2 Study of Dibotatug (DR-01), a Non-Fucosylated Anti-CD94 Antibody, in Patients with Relapsed/Refractory Cytotoxic T/NK cell Lymphomas

Swaminathan Iyer

Poster Presenter: Swaminathan Iyer

Thumbnail for Updated efficacy and safety data from an ongoing phase 1a/b trial of the Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across lines of therapy

CLL - 427

Updated efficacy and safety data from an ongoing phase 1a/b trial of the Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) across lines of therapy

Zulfa Omer

Poster Presenter: Zulfa Omer

Thumbnail for Updated Incidence Trends in Myelodysplastic Syndrome: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

MDS - 1422

Updated Incidence Trends in Myelodysplastic Syndrome: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database

Michael Asare

Poster Presenter: Michael Asare

Thumbnail for Updated Overall Survival (OS) and Long-Term Transfusion Independence (TI) From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS)

MDS - 113

Updated Overall Survival (OS) and Long-Term Transfusion Independence (TI) From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Guillermo Garcia-Manero

Poster Presenter: Guillermo Garcia-Manero

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors